Polymorphisms in CYP3A4 and CYP3A5, both encoding dominant enzymes involved in IM metabolism, have been described in several studies as correlated with IM resistance in CML patients [12]. The gene discussed is CYP3A5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.